openPR Logo
Press release

Acute Gout Flare Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, Olatec Therapeutics, Dyve Biosciences, LG Chem

06-04-2024 08:42 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Acute Gout Flare Market 2032: Epidemiology Data, Pipeline

DelveInsight's "Acute Gout Flare Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acute Gout Flare market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Gout Flare Market Forecast
https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Acute Gout Flare Market Report:
• The Acute Gout Flare market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2024, Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a biotechnology company in the clinical stage, focusing on developing top-tier therapies for inflammatory and metabolic conditions, has announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 clinical trial of ABP-745, an oral small molecule drug with anti-inflammatory properties, for treating acute gout. Atom has also submitted an IND application for a Phase 1 clinical trial of ABP-745 in China. Both studies will run concurrently in the United States and China.
• The overall occurrence of gout affects 1-4% of the general population. There is a higher susceptibility to gout in men compared to women. In Western countries, the prevalence is approximately 3-6% in men and 1-2% in women.
• Gout results in around 7 million outpatient visits in the United States each year, incurring a cost of almost USD 1 billion.
• Key Acute Gout Flare Companies: Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others
• Key Acute Gout Flare Therapies: Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others
• The Acute Gout Flare epidemiology based on gender analyzed that Gout is three times more prevalent in males than females
• The Acute Gout Flare market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Gout Flare pipeline products will significantly revolutionize the Acute Gout Flare market dynamics.

Acute Gout Flare Overview
An acute gout flare, also known simply as a gout attack, is a sudden and severe episode of inflammation and pain in a joint caused by the deposition of uric acid crystals. Gout is a form of arthritis characterized by elevated levels of uric acid in the blood, leading to the formation of these crystals, typically in the joints.

Get a Free sample for the Acute Gout Flare Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Gout Flare Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Gout Flare Epidemiology Segmentation:
The Acute Gout Flare market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Acute Gout Flare
• Prevalent Cases of Acute Gout Flare by severity
• Gender-specific Prevalence of Acute Gout Flare
• Diagnosed Cases of Episodic and Chronic Acute Gout Flare

Download the report to understand which factors are driving Acute Gout Flare epidemiology trends @ Acute Gout Flare Epidemiology Forecast
https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Gout Flare Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Gout Flare market or expected to get launched during the study period. The analysis covers Acute Gout Flare market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Gout Flare Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Gout Flare Therapies and Key Companies
• Dapansutrile: Olatec Therapeutics
• DYV700: Dyve Biosciences
• Genakumab for injection: Changchun GeneScience Pharma
• Rilonacept: Regeneron Pharmaceuticals
• ACZ885: Novartis
• Tigulixostat: LG Chem
• Canakinumab: Novartis
• MK0663: Organon and Co
• Bucillamine: Revive Therapeutics, Ltd.

Discover more about therapies set to grab major Acute Gout Flare market share @ Acute Gout Flare Treatment Landscape
https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Acute Gout Flare Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Gout Flare Companies: Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others
• Key Acute Gout Flare Therapies: Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others
• Acute Gout Flare Therapeutic Assessment: Acute Gout Flare current marketed and Acute Gout Flare emerging therapies
• Acute Gout Flare Market Dynamics: Acute Gout Flare market drivers and Acute Gout Flare market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acute Gout Flare Unmet Needs, KOL's views, Analyst's views, Acute Gout Flare Market Access and Reimbursement

To know more about Acute Gout Flare companies working in the treatment market, visit @ Acute Gout Flare Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acute Gout Flare Market Report Introduction
2. Executive Summary for Acute Gout Flare
3. SWOT analysis of Acute Gout Flare
4. Acute Gout Flare Patient Share (%) Overview at a Glance
5. Acute Gout Flare Market Overview at a Glance
6. Acute Gout Flare Disease Background and Overview
7. Acute Gout Flare Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Gout Flare
9. Acute Gout Flare Current Treatment and Medical Practices
10. Acute Gout Flare Unmet Needs
11. Acute Gout Flare Emerging Therapies
12. Acute Gout Flare Market Outlook
13. Country-Wise Acute Gout Flare Market Analysis (2019-2032)
14. Acute Gout Flare Market Access and Reimbursement of Therapies
15. Acute Gout Flare Market Drivers
16. Acute Gout Flare Market Barriers
17. Acute Gout Flare Appendix
18. Acute Gout Flare Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Graft Versus Host Disease Market http://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft-versus-host Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Implantable Cardioverter Defibrillators Market http://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
DelveInsight's 'Implantable Cardioverter Defibrillators (ICDs) - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Implantable Cardioverter Defibrillators (ICDs) and the historical and forecasted Implantable Cardioverter Defibrillators (ICDs) market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Gout Flare Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, Olatec Therapeutics, Dyve Biosciences, LG Chem here

News-ID: 3525953 • Views:

More Releases from DelveInsight Business Research

Menopause Market Expected to Gain Momentum Through 2034, According to DelveInsight
Menopause Market Expected to Gain Momentum Through 2034, According to DelveInsig …
DelveInsight's "Menopause Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Menopause, historical and forecasted epidemiology as well as the Menopause market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Menopause market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menopause Market Forecast https://www.delveinsight.com/sample-request/menopause-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Menopause
Exocrine Pancreatic Insufficiency Market Set for Robust Expansion Through 2034, DelveInsight Reports
Exocrine Pancreatic Insufficiency Market Set for Robust Expansion Through 2034, …
DelveInsight's "Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Exocrine Pancreatic Insufficiency, historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Exocrine Pancreatic Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Exocrine Pancreatic Insufficiency Market
EGFR Inhibitor Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight
EGFR Inhibitor Market Growth to Surge During Forecast Period (2024-2034), Says D …
DelveInsight's "EGFR Inhibitor Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the EGFR Inhibitor, historical and forecasted epidemiology as well as the EGFR Inhibitor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the EGFR Inhibitor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR Inhibitor Market Forecast https://www.delveinsight.com/sample-request/egfr-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Dysmenorrhea Market to Witness Promising Upswing by 2034, DelveInsight Forecasts
Dysmenorrhea Market to Witness Promising Upswing by 2034, DelveInsight Forecasts
DelveInsight's "Dysmenorrhea Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Dysmenorrhea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dysmenorrhea Market Forecast https://www.delveinsight.com/report-store/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Dysmenorrhea

All 5 Releases


More Releases for Gout

Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions. Download
Chronic Gout Market Massive Growth opportunity Ahead
Introduction Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032. Gout Therapeutics Market Introduction The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/reports/371311/gout-drugs Market
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications. Patients with multiple episodes of severe gout attacks every year or with